NEWRON PHARMA N news, videos and press releases
For more news please use our advanced search feature.
NEWRON PHARMA N - More news...
NEWRON PHARMA N - More news...
- EQS-News: Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
- EQS-News: Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
- EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
- EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
- EQS-News: Newron presents 2023 financial results and provides 2024 outlook
- EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
- EQS-News: Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
- EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
- EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
- EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
- EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
- EQS-News: Newron appoints Margarita Chavez as board advisor
- Newron Announces H1 2023 Results and Provides R&D Update
- EQS-News: Newron announces H1 2023 results and provides R&D update
- Newron Presents Exciting New Data From Study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
- EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
- Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
- EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
- Newron Announces Senior Management Team Changes
- EQS-News: Newron announces Senior Management Team changes
- EQS-News: Newron announces AGM 2023 results
- Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry
- EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
- Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
- EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
- Newron to present at the 31st European Congress of Psychiatry
- EQS-News: Newron to present at the 31st European Congress of Psychiatry
- Newron Announces 2022 Financial Results and Provides Outlook For 2023
- EQS-News: Newron announces 2022 financial results and provides outlook for 2023
- Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia